Home » Topics » Conferences

Conferences
RSS

More ACS news: preclinical profile of a novel protein farnesyltransferase inhibitor, Sch-207758

Sep. 2, 1999

Inhibitors of MMPs based on D-penicillamine presented by Agouron at ACS meeting

Sep. 2, 1999

Glaxo Wellcome selects anti-HCMV compound GW-275175X for further study

Sep. 2, 1999

Research at St. Charles Pharmaceuticals discussed at ACS

Sep. 2, 1999

CombiChem presents design and synthesis of selective D4 ligands at ACS meeting

Sep. 2, 1999

Antrin photoangioplasty safe and clinically active in PAD therapy

Sep. 2, 1999

ACS news: new compounds from Merck & Co. potently and selectively inhibit 5alpha-reductase type 1

Sep. 1, 1999

p38 inhibitor RPR-200765A designated candidate for development in arthritis Rx

Sep. 1, 1999

Sulfamide inhibitors of MMPs: synthesis and pharmacological data presented at ACS meeting

Sep. 1, 1999

More on Lilly's GH secretagogue program, including clinical candidate

Sep. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...